{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:16Z","timestamp":1791357496374,"version":"4.3.1"},"reference-count":91,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1631,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1111\/j.1755-5949.2011.00234.x","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T11:00:52Z","timestamp":1300186852000},"page":"110-117","source":"Crossref","is-referenced-by-count":35,"title":["Treatment Strategies for Dosing the Second Generation Antipsychotics"],"prefix":"10.1111","volume":"17","author":[{"given":"Thomas L.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.jcp.0000169623.30196.b9","article-title":"Dosing of second generation antipsychotic medication in a state hospital system","volume":"25","author":"Citrome","year":"2005","journal-title":"J Clin Psychopharm"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing of atypical antipsychotics in adults: A review of the current evidence","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv Rev Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB3|cit3","unstructured":""},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB4|cit4","unstructured":""},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB5|cit5","unstructured":""},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: Second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S1092852900020307","article-title":"Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study","volume":"14","author":"Weisler","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB8|cit8","volume-title":"Kaplan and Sadock's synopsis of psychiatry","year":"2003"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200519010-00003","article-title":"Switching between second-generation antipsychotics: Why and how?","volume":"19","author":"Eltanaihi-Furtm\u00fcller","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB10|cit10","volume-title":"Stahl's essential psychopharmacology: Neuroscientific basis and practical applications","author":"Stahl","year":"2008"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s002130050834","article-title":"Bymaster FP The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors","volume":"141","author":"Zhang","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)12023-5","article-title":"Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.pnpbp.2008.08.020","article-title":"Effect of ritanserin, a 5HT2A\/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.187.3.229","article-title":"Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study","volume":"187","author":"Khanna","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00148581-200709050-00006","article-title":"Risperidone: A review of its use in the treatment of irritability associated with autistic disorder in children and adolescents","volume":"9","author":"Scott","year":"2007","journal-title":"Paediatr Drugs"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychoticmajor depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hup.979","article-title":"Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline","volume":"23","author":"Yoshimura","year":"2008","journal-title":"Human Psychopharmacol."},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"Reeves","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.biopsych.2008.05.005","article-title":"Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications","volume":"64","author":"Sen","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.v69n0515","article-title":"Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies","volume":"69","author":"Meltzer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB24|cit24","unstructured":"2008"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB25|cit25","unstructured":"1995"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1176\/appi.ajp.2007.06111932","article-title":"Olanzapine versus placebo in the treatment of adolescents with bipolar mania","volume":"164","author":"Tohen","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1586\/ern.09.54","article-title":"Olanzapine dosing above the licensed range is more efficacious than lower doses: Fact or fiction?","volume":"9","author":"Citrome","year":"2009","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/JCP.0b013e3181a289cb","article-title":"Olanzapine plasma concentrations after treatment with 10,20,40mg\/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration","volume":"29","author":"Citrome","year":"2009","journal-title":"J Clin Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e31817e63a5","article-title":"Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed dose study","volume":"28","author":"Kinon","year":"2008","journal-title":"J Clin Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pscychresns.2005.08.003","article-title":"Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study","volume":"146","author":"Mathews","year":"2006","journal-title":"Psychiatry Res"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","article-title":"Efficacy of olanzapine in social anxiety disorder: A pilot study","volume":"16","author":"Barnett","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4088\/JCP.v67n0514","article-title":"A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression","volume":"67","author":"Corya","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/11203830-000000000-00000","article-title":"Olanzapine\/fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder","volume":"24","author":"Croxtall","year":"2010","journal-title":"CNS Drugs"},{"issue":"5 Suppl 9","key":"10.1111\/j.1755-5949.2011.00234.x-BIB36|cit36","first-page":"1","article-title":"Dosing Atypical antipsychotics","volume":"13","author":"Cutler","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1463-1326.2009.01038.x","article-title":"Obesity, serious mental illness and antipsychotic drugs","volume":"11","author":"Holt","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"4 Pt 3","key":"10.1111\/j.1755-5949.2011.00234.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/15622970903079507","article-title":"Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: Results from a six-month prospective, multinational, observational study","volume":"10","author":"Treuer","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB39|cit39","first-page":"169","article-title":"Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"PharmacolTher"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.psc.2009.08.003","article-title":"Management of schizophrenia with obesity, metabolic, and endocrinological disorders","volume":"32","author":"Monteleone","year":"2009","journal-title":"Psychiatr Clin N Am"},{"issue":"4","key":"10.1111\/j.1755-5949.2011.00234.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/10398560902842519","article-title":"An evaluation of monitoring practices in patients on second generation antipsychotics","volume":"17","author":"Nguyen","year":"2009","journal-title":"Australasian Psychiatry"},{"issue":"Suppl 3","key":"10.1111\/j.1755-5949.2011.00234.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.7075su1c.05","article-title":"Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses","volume":"70","author":"Newcomer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e328337789b","article-title":"Study 4 Investigators. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study","volume":"25","author":"Peuskens","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1185\/030079905X46340","article-title":"Quetiapine monotherapy for mania associated with bipolar disorder: Combined analysis of two international, double-blind, randomised, placebo-controlled studies","volume":"21","author":"Vieta","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB46|cit46","volume-title":"Essential psychopharmacology: The prescriber's guide","author":"Stahl","year":"2009"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/appi.ps.58.1.11","article-title":"The ups and downs of dosing second generation antipsychotics","volume":"58","author":"Citrome","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4088\/JCP.v66n1203","article-title":"Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies","volume":"66","author":"Citrome","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","article-title":"Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study","volume":"13","author":"Bandelow","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1586\/ern.09.37","article-title":"Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders","volume":"9","author":"Gao","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.33549\/physiolres.931756","article-title":"Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: Implications for the treatment of posttraumatic stress disorder","volume":"59","author":"Wang","year":"2010","journal-title":"Physiol Res"},{"issue":"Suppl. 1","key":"10.1111\/j.1755-5949.2011.00234.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0924-9338(10)71429-2","article-title":"Translational pharmacology of quetiapine and norquetiapine: Preclinical findings support multifunctional psychotropic properties","volume":"25","author":"Nyberg","year":"2010","journal-title":"Eur Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4088\/JCP.v69n1005","article-title":"Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: A randomized, double-blind, placebo-controlled crossover study","volume":"69","author":"Scharf","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neulet.2010.02.038","article-title":"Buspirone-induced changes in the serotonergic and non-serotonergic cells in the dorsal raphe nucleus of rats","volume":"473","author":"Jahanshahi","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0269881108100774","article-title":"The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice","volume":"24","author":"Shajahan","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/da.20275","article-title":"Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study","volume":"24","author":"McIntyre","year":"2007","journal-title":"Depress Anxiety"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/14656566.2.6.1033","article-title":"Ziprasidone: A new atypical antipsychotic","volume":"2","author":"Keck","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2165\/00023210-200721100-00004","article-title":"Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder","volume":"21","author":"Warrington","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB61|cit61","unstructured":"2001"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2009.09.023","article-title":"Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder","volume":"115","author":"Citrome","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4088\/JCP.08m04531","article-title":"How dosing of ziprasidone in a state hospital system differs from product labeling","volume":"70","author":"Citrome","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"supplement 19","key":"10.1111\/j.1755-5949.2011.00234.x-BIB64|cit64","first-page":"6","article-title":"The psychopharmacology of ziprasidone: Receptor-binding properties and real-world psychiatric practice","volume":"64","author":"Stahl","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"10 Suppl 11","key":"10.1111\/j.1755-5949.2011.00234.x-BIB65|cit65","first-page":"6","article-title":"Atypical Antipsychotics: Matching receptor profile to individual patient's clinical profile","volume":"9","author":"Shayegan","year":"2003","journal-title":"CNS Spectrums"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB66|cit66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2009.06.023","article-title":"Efficacy of Ziprasidone in Dysphoric Mania: Pooled analysis of 2 double blind studies","volume":"122","author":"Stahl","year":"2010","journal-title":"J Affect Disord"},{"issue":"5 Suppl 9","key":"10.1111\/j.1755-5949.2011.00234.x-BIB67|cit67","first-page":"1","article-title":"Expert review supplement dosing atypicals antipsychotics","volume":"13","author":"Cutler","year":"2008","journal-title":"CNS Spectrums"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2009.01.022","article-title":"Ziprasidone monotherapy in bipolar II depression: An open trial","volume":"118","author":"Liebowitz","year":"2009","journal-title":"J Affect Disord"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1755-5949.2008.00056.x","article-title":"Ziprasidone in the treatment of affective disorders: A review","volume":"14","author":"Rosa","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB70|cit70","first-page":"217","article-title":"Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder","volume":"65","author":"Papakostas","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.jcp.0000177853.15910.de","article-title":"Open-label pilot study of ziprasidone for refractory generalized anxiety disorder","volume":"25","author":"Snyderman","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4088\/JCP.v68n0714","article-title":"Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study","volume":"68","author":"Dunner","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"Pt 1","key":"10.1111\/j.1755-5949.2011.00234.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.clinthera.2009.07.004","article-title":"Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials","volume":"31","author":"Edwards","year":"2009","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"10.1111\/j.1755-5949.2011.00234.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.clinthera.2010.01.021","article-title":"Aripiprazole in schizophrenia and schizoaffective disorder: A review","volume":"32","author":"Stip","year":"2010","journal-title":"Clin Ther"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1192\/bjp.bp.108.049965","article-title":"Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study","volume":"194","author":"Young","year":"2009","journal-title":"B J Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.genhosppsych.2009.05.005","article-title":"Aripiprazole in major depression and mania: Meta-analyses of randomized placebo-controlled trials","volume":"31","author":"Arbaizar","year":"2009","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jad.2009.06.026","article-title":"Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies","volume":"120","author":"Nelson","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1017\/S109285290001676X","article-title":"Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder","volume":"13","author":"Hoge","year":"2008","journal-title":"Cns Spectrums"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.jcp.0000248620.34541.bc","article-title":"An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder","volume":"27","author":"Menza","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB81|cit81","unstructured":"2009"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","article-title":"Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial","volume":"122","author":"McIntyre","year":"2010","journal-title":"J Affect Disord"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2009.45.12.1421561","article-title":"Asenapine maleate: A new drug for the treatment of schizophrenia and bipolar mania","volume":"45","author":"Tarazi","year":"2009","journal-title":"Drugs of Today"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-008-1456-5","article-title":"Evidence for activation of cortical and subcortical dopamine systems by different mechanisms","volume":"204","author":"Franberg","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB86|cit86","unstructured":"2009"},{"issue":"2 Suppl 1","key":"10.1111\/j.1755-5949.2011.00234.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/JCP.0b013e3181692787","article-title":"Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies","volume":"28","author":"Potkin","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0024-3205(03)00419-3","article-title":"Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors","volume":"73","author":"Kalkman","year":"2003","journal-title":"Life Sci."},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2165\/10489070-000000000-00000","article-title":"Iloperidone: In schizophrenia","volume":"23","author":"Scott","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1586\/ern.09.119","article-title":"Iloperidone: A new option for the treatment of schizophrenia","volume":"9","author":"Cutler","year":"2009","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1111\/j.1755-5949.2011.00234.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1092852900000213","article-title":"Multifunctional drugs: A novel concept for psychopharmacology","volume":"14","author":"Stahl","year":"2009","journal-title":"Cns Spectrums"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2011.00234.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1755-5949.2011.00234.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T09:24:53Z","timestamp":1741080293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2011.00234.x"}},"subtitle":["Second Generation Antipsychotic Dosing Strategies"],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2011.00234.x","relation":{},"ISSN":["1755-5930"],"issn-type":[{"value":"1755-5930","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,15]]}}}